1.
Invest New Drugs
; 39(1): 237-239, 2021 02.
Artículo
en Inglés
| MEDLINE
| ID: mdl-32648118
RESUMEN
Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Asunto(s)
Nefritis Intersticial/inducido químicamente , Piperidinas/efectos adversos , Inhibidores de Proteínas Quinasas/efectos adversos , Quinazolinas/efectos adversos , Anciano , Humanos , Masculino , Piperidinas/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Quinazolinas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico
2.